Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual therapy with blinatumomab and TKIs may offer a safe and effective treatment option for relapsed and refractory Ph+ acute lymphoblastic leukemic patients

Next Previous
Search
Trial Profile

Dual therapy with blinatumomab and TKIs may offer a safe and effective treatment option for relapsed and refractory Ph+ acute lymphoblastic leukemic patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Bosutinib (Primary) ; Dasatinib (Primary) ; Nilotinib (Primary)
  • Indications Blast crisis; Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Dec 2019 New trial record
    • 06 Nov 2019 Results assessing effectiveness of blinatumomab with TKI combination therapy, released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top